映恩生物配售260万股 预计获2.35亿港元

财中社
07 May

映恩生物-B(09606)发布公告,公司于2025年5月6日悉数行使招股章程所述的超额配股权,涉及合共260万股股份,约占全球发售项下可供认购发售股份总数的15%。此次超额配发股份的发行价为每股94.6港元,预计将为公司带来约2.35亿港元的净额收入,扣除承销费用及佣金后,这笔资金将按招股章程所述的用途进行使用。公告中提到,超额配发股份将用于归还DualityBioLtd.的借股协议项下的股份。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10